Alphatec (NASDAQ:ATEC) Director Sells $636,000.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Demski sold 30,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $21.20, for a total value of $636,000.00. Following the sale, the director directly owned 399,623 shares of the company’s stock, valued at approximately $8,472,007.60. This represents a 6.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Alphatec Stock Performance

ATEC traded up $0.05 during trading on Friday, hitting $19.96. The stock had a trading volume of 1,836,465 shares, compared to its average volume of 2,006,404. Alphatec Holdings, Inc. has a twelve month low of $8.69 and a twelve month high of $22.66. The firm has a market capitalization of $2.97 billion, a P/E ratio of -19.19 and a beta of 1.08. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The company’s 50-day moving average price is $18.42 and its 200 day moving average price is $15.08.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The company’s revenue was up 30.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.28) earnings per share. On average, equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Alphatec

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LPL Financial LLC grew its stake in Alphatec by 1.2% during the 1st quarter. LPL Financial LLC now owns 418,061 shares of the medical technology company’s stock valued at $4,211,000 after purchasing an additional 4,826 shares in the last quarter. Vanguard Group Inc. raised its stake in Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock valued at $60,990,000 after buying an additional 45,792 shares in the last quarter. Deutsche Bank AG lifted its stake in Alphatec by 11.8% during the first quarter. Deutsche Bank AG now owns 1,185,235 shares of the medical technology company’s stock worth $12,018,000 after purchasing an additional 124,785 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Alphatec by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company’s stock valued at $413,000 after buying an additional 1,792 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Alphatec during the first quarter valued at approximately $973,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on ATEC shares. Loop Capital set a $25.00 target price on Alphatec in a report on Wednesday. Canaccord Genuity Group lifted their target price on shares of Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Wall Street Zen downgraded shares of Alphatec from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. HC Wainwright raised their price objective on Alphatec from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Lake Street Capital set a $25.00 price target on shares of Alphatec and gave the stock a “buy” rating in a research report on Friday, October 31st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and a consensus price target of $22.45.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.